Presentations & Publications
IpY.20, a first-in-class inhibitor of p27Kip1, inhibits CDK4/6 and CDK2 to kill tumor cell
Targeting p27Kip1 to inhibit CDK4/6/2 as a novel therapeutic strategy to treat pancreatic ductal adenocarcinoma
NP-ALT, a liposomal:peptide drug, blocks p27Kip1 phosphorylation to cause cell death in CDK4i-resistant breast cancer
Developing IpY: A novel inhibitor for the treatment of ER+ CDK4i-resistant breast cancer
Concarlo in the News
Many startups are built off research, so why don’t more scientists become founders?
Paving the Way: Bold Perspectives from Female Executives in Biotech featuring Krishna Allamneni
LIPOSOMAL PEPTIDE THERAPEUTICS – Revolutionizing Oncology: Unleashing Innovative Strategies to Tackle Challenging, High-Value Drug Targets
CDK Inhibitors: Why Women – and Men – Should Know About This ‘New Era’ Of Cancer Treatment
Webinars & Talks
Stacy Blain and Arthur Klausner on NewYorkBIOs Virtual Breakfast Series
Heroes of Healthcare – Episode 50: Shutting the Door on Cancer Cells
LabOps: Changing Outcomes for Drug-Resistant Patients with Stacy Blain, Founder, and CSO at Concarlo Therapeutics
Case Study: Developing liposomal formulation of a novel 91-mer synthetic peptide for treatment of ER+ CDK4i resistant Breast Cancer
Awards
“The reward for work well done is the opportunity to do more”
—Jonas Salk
Winner of 2025 TiE SoCal Women Founders
Pitch Competition
Top Therapeutic Company at Aquillius’ 2025 Innovation in Women’s Health Pitch Showcase
The 50 Most admired companies: CIO Bio
Top 100 entreprenuers: Alumni List
Top Biotech Startup 2022
Awarded by: Life Sciences Review
